Eton licenses Aquestive's Libervant seizure rescue film for exclusive US commercialisation

Eton Pharmaceuticals has secured exclusive US commercialisation rights to Aquestive Therapeutics' Libervant diazepam buccal film for the investigational treatment of seizure clusters.

The licensing and supply agreement gives Eton responsibility for US commercialisation while Aquestive remains the exclusive manufacturer and supplier of the diazepam buccal film formulation.

Aquestive is eligible for mid-teens royalties on annual net sales, with a potential April 2027 commercial launch dependent on final FDA approval.

Field	Content
Article Type	Deals
Companies	Eton Pharmaceuticals; Aquestive Therapeutics
Deal Type	Exclusive US licensing and supply agreement
Licensed Product	Libervant
Active Ingredient	Diazepam
Dosage Form	Buccal film
Therapeutic Area	Neurology; seizure clusters
Product Status	Investigational for the intended US commercial launch; final FDA approval pending
Licensing Rights	Exclusive US commercialisation rights granted to Eton
Manufacturing and Supply	Aquestive remains the exclusive manufacturer and supplier
Royalties	Mid-teens percentage of annual net sales
Upfront Payment	Not disclosed in supplied summary
Expected Commercial Launch	April 2027 subject to final FDA approval
Geography	United States
What Happened	Eton and Aquestive signed an exclusive US licensing and supply agreement for Libervant diazepam buccal film.
Why It Matters	The agreement establishes a dedicated commercial partner for a potential seizure-cluster rescue treatment while preserving Aquestive's manufacturing role.
Strategic Rationale	Eton gains a potential specialty neurology product while Aquestive retains supply responsibilities and participates in future sales through royalties.
Key Takeaway	Eton holds exclusive US commercialisation rights to Libervant but the product's anticipated launch depends on final FDA approval.
What to Watch	FDA regulatory decision, launch preparations, product availability, reimbursement and subsequent sales performance.
Primary Source	Eton Pharmaceuticals and Aquestive Therapeutics announcement
Relevant Date	14 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com